Article Text

Download PDFPDF
Assessment of myocardial viability: using coronary pressure and flow after acute myocardial infarction
  1. M J Kern
  1. Correspondence to:
    Morton J Kern, MD, J Gerard Mudd Cardiac Catheterization Laboratory, St Louis University Health Sciences Center, 3635 Vista Avenue at Grand Blvd, PO Box 15250, St Louis, MO 63110-0250, USA;
    kernm{at}slu.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Assessment of myocardial viability has been a challenge for revascularisation therapeutics in determining the effectiveness of an intervention and patient prognosis. In most cases, the current standard for viability is the recovery of function measured by left ventricular (LV) wall motion and the metabolic activity measured by positron emission tomography (PET) with the uptake of the metabolic tracer 18-fluoro-deoxyglucose (FDG). In this issue of Heart, Schimada and colleagues1 report how they coupled this imaging methodology of the metabolic activity of viable myocardium with other physiologic indices. In 27 patients, coronary flow and pressure were measured after successful angioplasty in patients undergoing acute myocardial infarction intervention within 12 hours of the onset of symptoms. FDG PET scan results and pressure at zero flow slope index, the SIFP, from simultaneously recorded aortic pressure and coronary flow velocity signals at peak hyperaemia, distal to the lesion in the re-canalised artery were compared. The percentage FDG uptake in the infarct myocardium was normalised for FDG uptake in …

View Full Text

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society